AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03228524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Aspartate
Description: Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
Study NCT03813550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fecal and blood samples
Description: Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
Study NCT03418870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Integrated Care
Description: Parents of infants assigned to mFI-Care will be trained and treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches.
Study NCT01828190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
Study NCT01868035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tositumomab and iodine I-131 tositumomab
Description: Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass.
Study NCT02318719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02318719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Study NCT03228524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Standard physiotherapy
Study NCT03228524 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic exercise
Description: Standard physiotherapy
Study NCT03228524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT04973371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test
Description: Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® \[Cepheid, Sunnyvale, CA\] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.
Study NCT01570270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CLA enriched cheese
Description: This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
Study NCT03290547 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cutera enLighten laser
Description: Subjects will receive laser treatments.
Study NCT00174967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
Study NCT00174967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
Study NCT00174967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
Study NCT00174967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
Study NCT03858803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Families Matter 2
Description: Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.
Study NCT03858803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living as a Safer Teen
Description: Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
Study NCT02704572 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Zostavax will be administrated by subcutaneous injection.
Study NCT02704572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax
Description: Zostavax will be administrated by subcutaneous injection.
Study NCT03933644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gastric Tube
Description: SGA is inserted with a gastric tube as guide for insertion
Study NCT03933644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: No gastric Tube
Description: SGA is inserted without a gastric tube as guide for insertion
Study NCT01604863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1036 + Paclitaxel + Carboplatin
Description: HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
Study NCT01604863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1036 + Cisplatin + Etoposide
Description: HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
Study NCT01604863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1036 + Docetaxel
Description: HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
Study NCT03703011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometers positioned at the wrinkle, the hip, and the ankle
Description: Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
Study NCT05855174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Weight protein provided in a shake with carbohydrate and water
Study NCT05855174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Weight protein provided in a shake with carbohydrate and water
Study NCT02996552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M & T Repair Group
Description: After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
Study NCT02996552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral-Only Group
Description: Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
Study NCT02716116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.
Study NCT03256370 — intervention group
Intervention type: PROCEDURE
Intervention: milk collection
Description: * Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method
Study NCT06523738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation
Description: 1. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation
Study NCT02328092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rSMS in treatment of Nocturnal Enuresis
Description: Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
Study NCT02328092 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rSMS in treatment of Nocturnal Enuresis
Description: Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
Study NCT01662531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rIX-FP
Description: Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
Study NCT02695602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdebrider-Assisted Inferior Turbinoplasty (MAIT)
Study NCT02695602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submucous Resection with non powered instrument
Study NCT01112514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Administered intravenously during endoscopic near-infrared (NIR) imaging
Study NCT05859802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine Pill
Description: Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking dalfampridine 10 mg two times day
Study NCT01732926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablet administered orally twice daily
Study NCT01732926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
Study NCT01732926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
Study NCT01732926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet administered orally twice daily
Study NCT03009877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow F&P 850™ System
Description: Optiflow™ (Fisher \& Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction.
Study NCT03009877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: facemask
Description: We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
Study NCT03009877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be administered after the ability to mask ventilate is determined.
Study NCT03009877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium will be administered after the ability to mask ventilate is determined.
Study NCT03009877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
Study NCT03009877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
Study NCT05859802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
Study NCT02461927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Naltrexone
Description: Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
Study NCT02461927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Placebo
Description: Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
Study NCT02461927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (psychoactive placebo midazolam) + Placebo
Description: Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
Study NCT04595539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation treatment with Attention Training Technique
Description: The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life.
Study NCT01562912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation Procedure
Description: Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
Study NCT01562912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVAC Ablation Procedure
Description: Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
Study NCT02721641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
Study NCT02948959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT02948959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT02948959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Controller Therapies
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral
Study NCT02948959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Controller Therapies
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral
Study NCT02948959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Reliever Therapies
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled
Study NCT03614078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRCL-02
Description: Oral tablets
Study NCT03614078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT02948959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Reliever Therapies
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled
Study NCT05258123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract
Description: Ginkgo biloba extract with 360mg was administered
Study NCT05258123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo with nine tables was administered
Study NCT01068314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive arm exercise
Description: After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
Study NCT01778946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Nicotine (7mg)
Study NCT01778946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate Dose Nicotine (14mg)
Study NCT02080195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
Study NCT02080195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day on Days -6 through -2.
Study NCT02080195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting on Day 5. Dose will be adjusted according to blood levels.
Study NCT02080195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg three times per day from Day 5 to Day 35.
Study NCT02080195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Description: 0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
Study NCT02080195 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 centigray on Day -1.
Study NCT02080195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant
Description: Infusion on Day 0.
Study NCT02275247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
Study NCT04563390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Projection-based augmented reality exposure therapy (P-ARET).
Description: The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention.
Study NCT04563390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo exposure therapy
Description: The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention.
Study NCT03607513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64264681
Description: For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.
Study NCT03607513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-64264681 will be administered as oral solution.
Study NCT01098149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BD and BVC, AFB
Description: Some patients are randomized into the AFB, the others into the BD and BVC
Study NCT03009877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
Study NCT04651049 — intervention group
Intervention type: DRUG
Intervention: propranolol
Description: This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.